Head-To-Head Comparison: Nanovibronix (NASDAQ:FEED) & Profusa (NASDAQ:PFSA)

Profusa (NASDAQ:PFSA) and Nanovibronix (NASDAQ:FEED) are both small-cap manufacturing companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Volatility and Risk

Profusa has a beta of -0.14, indicating that its share price is 114% less volatile than the S&P 500. Comparatively, Nanovibronix has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Profusa and Nanovibronix, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1	0	0	0	1.00
Nanovibronix	1	0	0	0	1.00

Institutional & Insider Ownership

9.8% of Profusa shares are owned by institutional investors. Comparatively, 16.4% of Nanovibronix shares are owned by institutional investors. 11.4% of Profusa shares are owned by insiders. Comparatively, 5.2% of Nanovibronix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Profusa and Nanovibronix”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	N/A	N/A	-$8.71 million	($2.23)	-1.42
Nanovibronix	$2.56 million	1.38	-$3.70 million	($41.74)	-0.08

Nanovibronix has higher revenue and earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Profusa and Nanovibronix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-880.32%
Nanovibronix	-275.12%	-24.78%	-19.24%

Summary

Nanovibronix beats Profusa on 5 of the 9 factors compared between the two stocks.

About Profusa

NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.

About Nanovibronix

NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.